Cargando…
Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance
Nonalcoholic fatty liver disease (NAFLD) is an escalating health problem that is frequently associated with obesity and insulin resistance. The mechanistic relationship between NAFLD, obesity, and insulin resistance is not well understood. A nonsynonymous variant in patatin-like phospholipase domain...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Wiley Subscription Services, Inc., A Wiley Company
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057507/ https://www.ncbi.nlm.nih.gov/pubmed/21274868 http://dx.doi.org/10.1002/hep.24072 |
_version_ | 1782200288382287872 |
---|---|
author | Kozlitina, Julia Boerwinkle, Eric Cohen, Jonathan C Hobbs, Helen H |
author_facet | Kozlitina, Julia Boerwinkle, Eric Cohen, Jonathan C Hobbs, Helen H |
author_sort | Kozlitina, Julia |
collection | PubMed |
description | Nonalcoholic fatty liver disease (NAFLD) is an escalating health problem that is frequently associated with obesity and insulin resistance. The mechanistic relationship between NAFLD, obesity, and insulin resistance is not well understood. A nonsynonymous variant in patatin-like phospholipase domain containing 3 (rs738409, I148M) has been reproducibly associated with increased hepatic triglyceride content (HTGC) but has not been associated with either the body mass index (BMI) or indices of insulin resistance. Conversely, two sequence variants in apolipoprotein C3 (APOC3) that have been linked to hypertriglyceridemia (rs2854117 C > T and rs2854116 T > C) have recently been reported to be associated with both hepatic fat content and insulin resistance. Here we genotyped two APOC3 variants in 1228 African Americans, 843 European Americans and 426 Hispanics from a multiethnic population based study, the Dallas Heart Study and test for association with HTGC and homeostatic model of insulin resistance (HOMA-IR). We also examined the relationship between these two variants and HOMA-IR in the Atherosclerosis Risk in Communities (ARIC) study. No significant difference in hepatic fat content was found between carriers and noncarriers in the Dallas Heart Study. Neither APOC3 variant was associated with HOMA-IR in the Dallas Heart Study; this lack of association was confirmed in the ARIC study, even after the analysis was restricted to lean (BMI < 25 kg/m(2)) individuals (n = 4399). Conclusion: Our data do not support a causal relationship between these two variants in APOC3 and either HTGC or insulin resistance in middle-aged men and women. (Hepatology 2011;53:467-474) |
format | Text |
id | pubmed-3057507 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Wiley Subscription Services, Inc., A Wiley Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-30575072012-02-01 Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance Kozlitina, Julia Boerwinkle, Eric Cohen, Jonathan C Hobbs, Helen H Hepatology Steatohepatitis/Metabolic Liver Disease Nonalcoholic fatty liver disease (NAFLD) is an escalating health problem that is frequently associated with obesity and insulin resistance. The mechanistic relationship between NAFLD, obesity, and insulin resistance is not well understood. A nonsynonymous variant in patatin-like phospholipase domain containing 3 (rs738409, I148M) has been reproducibly associated with increased hepatic triglyceride content (HTGC) but has not been associated with either the body mass index (BMI) or indices of insulin resistance. Conversely, two sequence variants in apolipoprotein C3 (APOC3) that have been linked to hypertriglyceridemia (rs2854117 C > T and rs2854116 T > C) have recently been reported to be associated with both hepatic fat content and insulin resistance. Here we genotyped two APOC3 variants in 1228 African Americans, 843 European Americans and 426 Hispanics from a multiethnic population based study, the Dallas Heart Study and test for association with HTGC and homeostatic model of insulin resistance (HOMA-IR). We also examined the relationship between these two variants and HOMA-IR in the Atherosclerosis Risk in Communities (ARIC) study. No significant difference in hepatic fat content was found between carriers and noncarriers in the Dallas Heart Study. Neither APOC3 variant was associated with HOMA-IR in the Dallas Heart Study; this lack of association was confirmed in the ARIC study, even after the analysis was restricted to lean (BMI < 25 kg/m(2)) individuals (n = 4399). Conclusion: Our data do not support a causal relationship between these two variants in APOC3 and either HTGC or insulin resistance in middle-aged men and women. (Hepatology 2011;53:467-474) Wiley Subscription Services, Inc., A Wiley Company 2011-02 /pmc/articles/PMC3057507/ /pubmed/21274868 http://dx.doi.org/10.1002/hep.24072 Text en Copyright © 2010 American Association for the Study of Liver Diseases http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Steatohepatitis/Metabolic Liver Disease Kozlitina, Julia Boerwinkle, Eric Cohen, Jonathan C Hobbs, Helen H Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance |
title | Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance |
title_full | Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance |
title_fullStr | Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance |
title_full_unstemmed | Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance |
title_short | Dissociation Between APOC3 Variants, Hepatic Triglyceride Content and Insulin Resistance |
title_sort | dissociation between apoc3 variants, hepatic triglyceride content and insulin resistance |
topic | Steatohepatitis/Metabolic Liver Disease |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057507/ https://www.ncbi.nlm.nih.gov/pubmed/21274868 http://dx.doi.org/10.1002/hep.24072 |
work_keys_str_mv | AT kozlitinajulia dissociationbetweenapoc3variantshepatictriglyceridecontentandinsulinresistance AT boerwinkleeric dissociationbetweenapoc3variantshepatictriglyceridecontentandinsulinresistance AT cohenjonathanc dissociationbetweenapoc3variantshepatictriglyceridecontentandinsulinresistance AT hobbshelenh dissociationbetweenapoc3variantshepatictriglyceridecontentandinsulinresistance |